Biotech leaders often fixate on share price after an IPO, but trading volume is the more important metric for long-term health. High liquidity attracts institutional investors and makes it easier to raise future capital. A stock that "trades by appointment" due to low volume signals a lack of interest and severely limits a company's financial options.

The biggest venture outcomes often take 8-10 years or more to mature. Instead of optimizing for quick IRR, early-stage VCs should embrace long holding periods. This "duration" is a feature that allows for massive value creation and aligns with building truly transformative companies, prioritizing multiples over short-term gains.

Timing a key data readout is critical for a newly public biotech. A readout in under three months is too soon, as investors will simply wait for the results before buying. Waiting longer than a year risks losing market relevance. The optimal window to maintain momentum is 6-12 months post-IPO.

In the current market, companies prioritize liquidity and public market access over protecting previous private valuations. A lower IPO price is no longer seen as a failure but as a necessary market correction to move forward and ensure survival.

The paper wealth generated on IPO day is a misleading metric due to lockup periods and market volatility. A more accurate mental model for an investor's actual return is the company's market capitalization 18 months after the public offering. This timeframe provides a truer 'locked in value' after initial hype and selling pressure subsides.

The modern market is driven by short-term incentives, with hedge funds and pod shops trading based on quarterly estimates. This creates volatility and mispricing. An investor who can withstand short-term underperformance and maintain a multi-year view can exploit these structural inefficiencies.

Despite private capital availability, the scrutiny of being a public company imposes healthy discipline. It forces better prioritization and maturity, which is ultimately beneficial for long-term growth and provides access to the world's deepest capital pools.

Contrary to the traditional focus on institutional investors, allocating a significant portion of an IPO to retail investors creates a loyal shareholder base. This "retail following" can result in higher valuation multiples and sustained brand advocacy, turning customers into long-term owners and a strategic asset.

An IPO is not a final exit but the start of a public "marriage" with new responsibilities. This mindset shifts focus from the event itself to rigorously preparing the company for the long-term demands of public markets, for instance through simulated earnings calls and disciplined share allocation to long-term investors.